Full Schedule

Home
Full Schedule

All Days
Wed, Jun 28
Thu, Jun 29
Fri, Jun 30
Sat, Jul 1

Full Schedule

Type here to filter the list

Thursday, June 29, 2023
08:00 – 09:25 CEST
Session IV: ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)
Session Chair: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute
Session Chair: Rille Pihlak, MD, PhD – St Bart's Hospital

08:00 – 09:25 CEST

Session IV: ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)

Session Chair: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute

Session Chair: Rille Pihlak, MD, PhD – St Bart's Hospital

Favorite

Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia ### 748626###Session Chair###Head of Department, Professor###Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia###
Session Chair: Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
### he/him/his @@@ Deniz Can Güven, MD – Hacettepe University Cancer Institute ### 1940200###Session Chair###Medical Oncologist###Hacettepe University Cancer Institute###
Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute
### @@@ Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital ### 1293161###Session Chair###Consultant Medical Oncologist###St Bart's Hospital###
Session Chair: Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital
### she/her/hers

08:00 – 08:15 CEST

News and Current State of Research in Anal Cancers

Speaker: Sheela Rao, MBBS FRCP MD (Res ) – Royal Marsden Hospital

Favorite

Sheela Rao, MBBS FRCP MD (Res ) (she/her/hers) – Royal Marsden Hospital ### 1940204###Speaker###Consultant Medical Oncologist ###Royal Marsden Hospital###
Speaker: Sheela Rao, MBBS FRCP MD (Res ) (she/her/hers) – Royal Marsden Hospital
### she/her/hers

08:15 – 08:30 CEST

News and Current State of Research in Small Bowel Adenocarcinoma

Speaker: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay

Favorite

Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay ### 710546###Speaker###Head of Gastrointestinal Oncology Unit###Gustave Roussy, Université Paris-Saclay###
Speaker: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay
###

08:30 – 08:45 CEST

Q&A and Panel Disussion

Moderator: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

Moderator: Deniz Can Güven, MD – Hacettepe University Cancer Institute

Moderator: Rille Pihlak, MD, PhD – St Bart's Hospital

Panelist: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay

Panelist: Sheela Rao, MBBS FRCP MD (Res ) – Royal Marsden Hospital

Favorite

Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia ### 748626###Moderator###Head of Department, Professor###Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia###
Moderator: Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
### he/him/his @@@ Deniz Can Güven, MD – Hacettepe University Cancer Institute ### 1940200###Moderator###Medical Oncologist###Hacettepe University Cancer Institute###
Moderator: Deniz Can Güven, MD – Hacettepe University Cancer Institute
### @@@ Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital ### 1293161###Moderator###Consultant Medical Oncologist###St Bart's Hospital###
Moderator: Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital
### she/her/hers @@@ Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay ### 710546###Panelist###Head of Gastrointestinal Oncology Unit###Gustave Roussy, Université Paris-Saclay###
Panelist: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay
### @@@ Sheela Rao, MBBS FRCP MD (Res ) (she/her/hers) – Royal Marsden Hospital ### 1940204###Panelist###Consultant Medical Oncologist ###Royal Marsden Hospital###
Panelist: Sheela Rao, MBBS FRCP MD (Res ) (she/her/hers) – Royal Marsden Hospital
### she/her/hers

08:45 – 09:00 CEST

Creating National and International Registries in GI Tumors

Favorite

09:00 – 09:15 CEST

Opportunities and Challenges of Building Trials in Rarer GI Subtypes

Speaker: Myriam Chalabi, MD PhD – Netherlands Cancer Institute

Favorite

Myriam Chalabi, MD PhD – Netherlands Cancer Institute ### 1560499###Speaker###Medical Oncologist, Clinical Group Leader###Netherlands Cancer Institute ###
Speaker: Myriam Chalabi, MD PhD – Netherlands Cancer Institute
###

09:15 – 09:25 CEST

Q&A and Panel Disussion

Moderator: Deniz Can Güven, MD – Hacettepe University Cancer Institute

Moderator: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia

Moderator: Rille Pihlak, MD, PhD – St Bart's Hospital

Panelist: Myriam Chalabi, MD PhD – Netherlands Cancer Institute

Favorite

Deniz Can Güven, MD – Hacettepe University Cancer Institute ### 1940200###Moderator###Medical Oncologist###Hacettepe University Cancer Institute###
Moderator: Deniz Can Güven, MD – Hacettepe University Cancer Institute
### @@@ Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia ### 748626###Moderator###Head of Department, Professor###Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia###
Moderator: Andrés Cervantes, MD, PhD (he/him/his) – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de Valencia
### he/him/his @@@ Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital ### 1293161###Moderator###Consultant Medical Oncologist###St Bart's Hospital###
Moderator: Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital
### she/her/hers @@@ Myriam Chalabi, MD PhD – Netherlands Cancer Institute ### 1560499###Panelist###Medical Oncologist, Clinical Group Leader###Netherlands Cancer Institute ###
Panelist: Myriam Chalabi, MD PhD – Netherlands Cancer Institute
###

08:00 – 09:35 CEST
Session V: Presentation of Selected Non-Colorectal Cancer Abstracts – Biliary Tract and Pancreatic Cancer

08:00 – 09:35 CEST

Session V: Presentation of Selected Non-Colorectal Cancer Abstracts – Biliary Tract and Pancreatic Cancer

Favorite

Andrzej Deptala (he/him/his) – Medical University of Warsaw ### 1852958###Chair###Chairman of the Department of Oncology Propaedeutics###Medical University of Warsaw###
Chair: Andrzej Deptala (he/him/his) – Medical University of Warsaw
### he/him/his @@@ Gerald Prager, MD – Medizinische Universität Wien ### 716608###Chair###Associate Professor###Medizinische Universität Wien###
Chair: Gerald Prager, MD – Medizinische Universität Wien
###

08:00 – 08:08 CEST

SO-1: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma

Abstract Presenter: James Harding

Favorite

James Harding ### 1977591###Abstract Presenter#########
Abstract Presenter: James Harding
###

08:08 – 08:16 CEST

SO-2: Quantitative Risk-benefit Assessment of Ivosidenib Compared to Placebo in Patients with IDH1-mutated Intrahepatic Cholangiocarcinoma: Phase 3 ClarIDHy trial

Abstract Presenter: Juan W. Valle, MD – University of Manchester, The Christie NHS Foundation Trust

Favorite

Juan W. Valle, MD – University of Manchester, The Christie NHS Foundation Trust ### 1003980###Abstract Presenter###Professor, Honorary Consultant in Medical Oncology###University of Manchester, The Christie NHS Foundation Trust###
Abstract Presenter: Juan W. Valle, MD – University of Manchester, The Christie NHS Foundation Trust
###

08:16 – 08:24 CEST

SO-3: Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: preliminary results from the multicenter B-REAL study

Abstract Presenter: Monica Niger

Favorite

Monica Niger ### 1977599###Abstract Presenter#########
Abstract Presenter: Monica Niger
###

08:24 – 08:32 CEST

SO-4: Impact of molecular profiling on survival in patients with advanced biliary tract cancers

Abstract Presenter: Leony Antoun

Favorite

Leony Antoun ### 1977601###Abstract Presenter#########
Abstract Presenter: Leony Antoun
###

08:32 – 08:40 CEST

SO-5: Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

Abstract Presenter: Antoine Hollebecque

Favorite

Antoine Hollebecque ### 1977602###Abstract Presenter#########
Abstract Presenter: Antoine Hollebecque
###

08:40 – 08:50 CEST

Discussant: SO-1, SO-2, SO-3, SO-4, SO-5

Discussant: Teresa Macarulla, MD, PhD – Vall d’Hebrón University Hospital

Favorite

Teresa Macarulla, MD, PhD (she/her/hers) – Vall d’Hebrón University Hospital ### 803555###Discussant###Head of Gastrointestinal and Endocrine Tumor Unit###Vall d’Hebrón University Hospital###
Discussant: Teresa Macarulla, MD, PhD (she/her/hers) – Vall d’Hebrón University Hospital
### she/her/hers

08:50 – 09:00 CEST

LBA-1: The Phase III study: Targeted Intra-Arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)

Abstract Presenter: Michael J. Pishvaian, MD, PhD – Johns Hopkins University

Favorite

Michael J. Pishvaian, MD, PhD – Johns Hopkins University ### 716607###Abstract Presenter###Associate Professor###Johns Hopkins University###
Abstract Presenter: Michael J. Pishvaian, MD, PhD – Johns Hopkins University
###

09:00 – 09:08 CEST

SO-6: Changes in the Course of Advanced Pancreatic Cancer Treatment With Systemic Chemotherapy: A Pooled Analyses of Five Clinical Trials From Two Decades of Clinical Research Within the German AIO Study-Group

Abstract Presenter: Lena Weiss

Favorite

Lena Weiss ### 1977603###Abstract Presenter#########
Abstract Presenter: Lena Weiss
###

09:08 – 09:16 CEST

SO-7: First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study

Abstract Presenter: Changhoon Yoo

Favorite

Changhoon Yoo ### 1977604###Abstract Presenter#########
Abstract Presenter: Changhoon Yoo
###

09:16 – 09:24 CEST

SO-8: Predictive Values of Blood-Based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer

Abstract Presenter: David Piquemal

Favorite

David Piquemal ### 1977605###Abstract Presenter#########
Abstract Presenter: David Piquemal
###

09:24 – 09:35 CEST

Discussant: LBA-1, SO-6, SO-7, SO-8

Discussant: Gerald Prager, MD – Medizinische Universität Wien

Favorite

Gerald Prager, MD – Medizinische Universität Wien ### 716608###Discussant###Associate Professor###Medizinische Universität Wien###
Discussant: Gerald Prager, MD – Medizinische Universität Wien
###

08:00 – 09:25 CEST
Session VI: Presentation of Selected Non-Colorectal Cancer Abstracts - Esophageal and Stomach Cancers

08:00 – 09:25 CEST

Session VI: Presentation of Selected Non-Colorectal Cancer Abstracts - Esophageal and Stomach Cancers

Favorite

Florian Lordick, MD, PhD (he/him/his) – Leipzig University Medical Center ### 716591###Chair###Professor of Oncology, Head of Department, Medical Director###Leipzig University Medical Center###
Chair: Florian Lordick, MD, PhD (he/him/his) – Leipzig University Medical Center
### he/him/his @@@ Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne ### 716602###Chair###Senior lecturer and consultant, head upper GI unit###Lausanne University Hospital, University of Lausanne###
Chair: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne
###

08:00 – 08:10 CEST

O-3: Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer

Abstract Presenter: Lucjan Wyrwicz

Favorite

Lucjan Wyrwicz ### 1666061###Abstract Presenter#########
Abstract Presenter: Lucjan Wyrwicz
###

08:10 – 08:20 CEST

O-4: GEMSTONE-304: a phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

Abstract Presenter: Jin Li

Favorite

Jin Li ### 1977606###Abstract Presenter#########
Abstract Presenter: Jin Li
###

08:20 – 08:28 CEST

SO-10: Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification

Abstract Presenter: Taroh Satoh

Favorite

Taroh Satoh ### 1977607###Abstract Presenter#########
Abstract Presenter: Taroh Satoh
###

08:28 – 08:38 CEST

Discussant: O-3, O-4, SO-10

Discussant: Florian Lordick, MD, PhD – Leipzig University Medical Center

Favorite

Florian Lordick, MD, PhD (he/him/his) – Leipzig University Medical Center ### 716591###Discussant###Professor of Oncology, Head of Department, Medical Director###Leipzig University Medical Center###
Discussant: Florian Lordick, MD, PhD (he/him/his) – Leipzig University Medical Center
### he/him/his

08:38 – 08:48 CEST

O-5: Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG

Abstract Presenter: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne

Favorite

Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne ### 716602###Abstract Presenter###Senior lecturer and consultant, head upper GI unit###Lausanne University Hospital, University of Lausanne###
Abstract Presenter: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne
###

08:48 – 08:56 CEST

SO-9: The relationship between primary tumour infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial

Abstract Presenter: Maximilian Kloft

Favorite

Maximilian Kloft ### 1007364###Abstract Presenter#########
Abstract Presenter: Maximilian Kloft
###

08:56 – 09:04 CEST

SO-11: Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)

Abstract Presenter: Zev A. Wainberg, MD, Msc – UCLA School of Medicine

Favorite

Zev A. Wainberg, MD, Msc – UCLA School of Medicine ### 983900###Abstract Presenter###Associate Professor of Medicine###UCLA School of Medicine###
Abstract Presenter: Zev A. Wainberg, MD, Msc – UCLA School of Medicine
###

09:04 – 09:12 CEST

SO-12: CLDN18.2 expression in resectable gastroesophageal cancers: associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity

Abstract Presenter: Antonella Cammarota

Favorite

Antonella Cammarota ### 1977608###Abstract Presenter#########
Abstract Presenter: Antonella Cammarota
###

09:12 – 09:25 CEST

Discussant: O-5, SO-9, SO-11, SO-12

Discussant: Kohei Shitara, MD – National Cancer Center Hospital East

Favorite

Kohei Shitara, MD – National Cancer Center Hospital East ### 716598###Discussant###Director###National Cancer Center Hospital East###
Discussant: Kohei Shitara, MD – National Cancer Center Hospital East
###

08:00 – 08:45 CEST
Session VII: Meet the Experts: How to Select Patients for TKIs in HCC?
Session Chair: Arndt Vogel, MD – Medizinische Hochschule Hannover

08:00 – 08:45 CEST

Session VII: Meet the Experts: How to Select Patients for TKIs in HCC?

Session Chair: Arndt Vogel, MD – Medizinische Hochschule Hannover

Favorite

Arndt Vogel, MD – Medizinische Hochschule Hannover ### 716621###Session Chair###Senior Consultant###Medizinische Hochschule Hannover###
Session Chair: Arndt Vogel, MD – Medizinische Hochschule Hannover
###

08:00 – 08:45 CEST

Expert Panel Discussion

Panelist: Maria Reig, MD, PhD – Hospital Clinic Barcelona

Panelist: Lorenza Rimassa, MD – Humanitas University and IRCCS Humanitas Research Hospital

Panelist: Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium)

Favorite

Maria Reig, MD, PhD – Hospital Clinic Barcelona ### 1003981###Panelist###Head of Liver Cancer Unit###Hospital Clinic Barcelona###
Panelist: Maria Reig, MD, PhD – Hospital Clinic Barcelona
### @@@ Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital ### 1666115###Panelist###Associate Professor of Medical Oncology###Humanitas University and IRCCS Humanitas Research Hospital###
Panelist: Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital
### she/her/hers @@@ Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium) ### 716620###Panelist###Professor###University Hospital Gasthuisberg Leuven (Belgium)###
Panelist: Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium)
###

09:30 – 10:00 CEST
Break and Poster Viewing

09:30 – 10:00 CEST

Break and Poster Viewing

Favorite

09:35 – 09:55 CEST

Poster Discussion Guided Tours - Group 1: Gastric Cancer and Pathology

Poster Discussant: Fatima Carneiro, MD, PhD – Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP)

Favorite

Fatima Carneiro, MD, PhD – Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP) ### 716594###Poster Discussant###Professor###Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP)###
Poster Discussant: Fatima Carneiro, MD, PhD – Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP)
###

09:35 – 09:55 CEST

Poster Discussion Guided Tours - Group 2: Gastric and Esophageal Cancers I

Poster Discussant: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom

Favorite

Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom ### 716617###Poster Discussant###Consultant Oncologist###Oxford Cancer, United Kingdom###
Poster Discussant: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom
###

09:35 – 09:55 CEST

Poster Discussion Guided Tours - Group 3: Gastric and Esophageal Cancers II

Poster Discussant: Radka Obermannova, MD, PhD – Masaryk Memorial Cancer Institute and Masaryk University

Favorite

Radka Obermannova, MD, PhD – Masaryk Memorial Cancer Institute and Masaryk University ### 957859###Poster Discussant###Senior Consultant, Head of Phase I Unit###Masaryk Memorial Cancer Institute and Masaryk University###
Poster Discussant: Radka Obermannova, MD, PhD – Masaryk Memorial Cancer Institute and Masaryk University
###

10:00 – 13:15 CEST
Session VIII: Esophageal and Gastric Cancers
Chair: Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland
Chair: Kohei Shitara, MD – National Cancer Center Hospital East

10:00 – 13:15 CEST

Session VIII: Esophageal and Gastric Cancers

Chair: Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland

Chair: Kohei Shitara, MD – National Cancer Center Hospital East

Favorite

Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland ### 1671191###Chair###Deputy Head of Medical Oncology Head of Gastrointestinal cancer Unit###Medical Oncology Department, Oncology Institute of Southern Switzerland###
Chair: Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland
### @@@ Kohei Shitara, MD – National Cancer Center Hospital East ### 716598###Chair###Director###National Cancer Center Hospital East###
Chair: Kohei Shitara, MD – National Cancer Center Hospital East
###

10:00 – 10:20 CEST

Endoscopic Management of Early Esophageal and Gastric Cancer

Favorite

Rehan Haidry ### 1968775###Invited Speaker#########
Invited Speaker: Rehan Haidry
###

10:20 – 10:40 CEST

Strategy in Oligometastatic Upper GI Cancer

Speaker: Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC

Favorite

Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC ### 1919811###Speaker###Head of the Department of Medical Oncology###Amsterdam UMC###
Speaker: Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC
###

10:40 – 10:50 CEST

O-6: EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study

Abstract Presenter: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom

Favorite

Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom ### 716617###Abstract Presenter###Consultant Oncologist###Oxford Cancer, United Kingdom###
Abstract Presenter: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom
###

10:50 – 11:00 CEST

O-7: Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577

Abstract Presenter: Ronan Kelly

Favorite

Ronan Kelly ### 1977609###Abstract Presenter#########
Abstract Presenter: Ronan Kelly
###

11:00 – 11:20 CEST

Are We Ready to Integrate Immunotherapy in Adjuvant and/or Neoadjuvant Settings in Upper GI Cancer? And Discussant (O-6 and O-7)

Speaker: Salah-Eddin Al-Batran, Prof. Dr. – Krankenhaus Nordwest, Frankfurt

Favorite

Salah-Eddin Al-Batran, Prof. Dr. (he/him/his) – Krankenhaus Nordwest, Frankfurt ### 1560486###Speaker###Medical Director###Krankenhaus Nordwest, Frankfurt###
Speaker: Salah-Eddin Al-Batran, Prof. Dr. (he/him/his) – Krankenhaus Nordwest, Frankfurt
### he/him/his

11:20 – 11:40 CEST

Keynote Lecture: Molecular Classification of Gastric Cancer

Speaker: Patrick Tan, MD. PhD – Duke-NUS Medical School

Favorite

Patrick Tan, MD. PhD (he/him/his) – Duke-NUS Medical School ### 1919813###Speaker###Professor###Duke-NUS Medical School###
Speaker: Patrick Tan, MD. PhD (he/him/his) – Duke-NUS Medical School
### he/him/his

11:40 – 11:48 CEST

SO-13: Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Abstract Presenter: Giovanni Randon

Favorite

Giovanni Randon ### 1977610###Abstract Presenter#########
Abstract Presenter: Giovanni Randon
###

11:48 – 11:58 CEST

Flash: Locally Advanced MSI-H Upper GI Cancer: What is the Optimal Approach?

Speaker: Filippo Pietrantonio, Dr – Fondazione IRCCS Istituto Nazionale dei Tumori

Favorite

Filippo Pietrantonio, Dr (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori ### 1919816###Speaker###MD###Fondazione IRCCS Istituto Nazionale dei Tumori###
Speaker: Filippo Pietrantonio, Dr (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori
### he/him/his

11:58 – 12:18 CEST

Checkpoint Inhibition in Squamous Cell Cancer of the Esophagus

Speaker: Markus Moehler, MD – Universitätsmedizin Mainz

Favorite

Markus Moehler, MD (he/him/his) – Universitätsmedizin Mainz ### 983893###Speaker###Consultant###Universitätsmedizin Mainz###
Speaker: Markus Moehler, MD (he/him/his) – Universitätsmedizin Mainz
### he/him/his

12:18 – 12:38 CEST

Checkpoint Inhibition in Metastatic Gastric Adenocarcinoma

Speaker: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom

Favorite

Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom ### 716617###Speaker###Consultant Oncologist###Oxford Cancer, United Kingdom###
Speaker: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom
###

12:38 – 13:15 CEST

New Targets and Agents in Upper GI Cancer

Speaker: Kohei Shitara, MD – National Cancer Center Hospital East

Favorite

Kohei Shitara, MD – National Cancer Center Hospital East ### 716598###Speaker###Director###National Cancer Center Hospital East###
Speaker: Kohei Shitara, MD – National Cancer Center Hospital East
###

13:00 – 13:15 CEST

Q&A and Panel Discussion

Moderator: Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland

Moderator: Kohei Shitara, MD – National Cancer Center Hospital East

Panelist: Salah-Eddin Al-Batran, Prof. Dr. – Krankenhaus Nordwest, Frankfurt

Panelist: Markus Moehler, MD – Universitätsmedizin Mainz

Panelist: Filippo Pietrantonio, Dr – Fondazione IRCCS Istituto Nazionale dei Tumori

Panelist: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom

Panelist: Patrick Tan, MD. PhD – Duke-NUS Medical School

Panelist: Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC

Favorite

Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland ### 1671191###Moderator###Deputy Head of Medical Oncology Head of Gastrointestinal cancer Unit###Medical Oncology Department, Oncology Institute of Southern Switzerland###
Moderator: Sara De Dosso, MD – Medical Oncology Department, Oncology Institute of Southern Switzerland
### @@@ Kohei Shitara, MD – National Cancer Center Hospital East ### 716598###Moderator###Director###National Cancer Center Hospital East###
Moderator: Kohei Shitara, MD – National Cancer Center Hospital East
### @@@ Salah-Eddin Al-Batran, Prof. Dr. (he/him/his) – Krankenhaus Nordwest, Frankfurt ### 1560486###Panelist###Medical Director###Krankenhaus Nordwest, Frankfurt###
Panelist: Salah-Eddin Al-Batran, Prof. Dr. (he/him/his) – Krankenhaus Nordwest, Frankfurt
### he/him/his @@@ Rehan Haidry ### 1968775###Invited Panelist#########
Invited Panelist: Rehan Haidry
### @@@ Markus Moehler, MD (he/him/his) – Universitätsmedizin Mainz ### 983893###Panelist###Consultant###Universitätsmedizin Mainz###
Panelist: Markus Moehler, MD (he/him/his) – Universitätsmedizin Mainz
### he/him/his @@@ Filippo Pietrantonio, Dr (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori ### 1919816###Panelist###MD###Fondazione IRCCS Istituto Nazionale dei Tumori###
Panelist: Filippo Pietrantonio, Dr (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori
### he/him/his @@@ Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom ### 716617###Panelist###Consultant Oncologist###Oxford Cancer, United Kingdom###
Panelist: Elizabeth C. Smyth, MD – Oxford Cancer, United Kingdom
### @@@ Patrick Tan, MD. PhD (he/him/his) – Duke-NUS Medical School ### 1919813###Panelist###Professor###Duke-NUS Medical School###
Panelist: Patrick Tan, MD. PhD (he/him/his) – Duke-NUS Medical School
### he/him/his @@@ Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC ### 1919811###Panelist###Head of the Department of Medical Oncology###Amsterdam UMC###
Panelist: Hanneke Van Laarhoven, MD, PhD – Amsterdam UMC
###

13:15 – 13:30 CEST
Break

13:15 – 13:30 CEST

Break

Favorite

13:30 – 15:00 CEST
Concurrent Lunch Symposia

13:30 – 15:00 CEST

Lunch Symposium: At the Cutting Edge of Treatment for mCRC: Newest Data and Guidance Supported by Merck Healthcare KGaA

Favorite

13:30 – 15:00 CEST

Lunch Symposium: Clinical Decision Making in Early Stage Gastric Cancer—A Multi-Disciplinary Team Approach Supported by MSD Merck

Favorite

13:30 – 15:00 CEST

Lunch Symposium: Expanding Horizons in BTC Patient Care: Improving Diagnosis and Outcomes Supported by AstraZeneca

Favorite

13:30 – 15:00 CEST

Lunch Symposium: Further Extending the Continuum of Care in mCRC Supported by Servier International Medical Affairs

Favorite

15:15 – 18:15 CEST
Session IX: Hepatocellular Cancer

15:15 – 17:55 CEST

Session IX: Hepatocellular Cancer

Favorite

Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay ### 710546###Chair###Head of Gastrointestinal Oncology Unit###Gustave Roussy, Université Paris-Saclay###
Chair: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay
### @@@ Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital ### 1252920###Chair###Consultant Medical Oncologist###Fundacion Jimenez Diaz University Hospital###
Chair: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital
###

15:15 – 15:35 CEST

Pathogenesis and Subtypes of HCC: NASH & Viral Etiology

Speaker: Jessica Zucman-Rossi, MD, PhD – Université Paris Cité

Favorite

Jessica Zucman-Rossi, MD, PhD (she/her/hers) – Université Paris Cité ### 1252784###Speaker###Professor of Medicine Head of the Cordeliers Research center###Université Paris Cité###
Speaker: Jessica Zucman-Rossi, MD, PhD (she/her/hers) – Université Paris Cité
### she/her/hers

15:35 – 15:55 CEST

Diagnostic and Imaging Challenges in HCC

Speaker: Jordi Rimola, MD PhD – Hospital Clínic Barcelona

Favorite

Jordi Rimola, MD PhD (he/him/his) – Hospital Clínic Barcelona ### 1968790###Speaker###Consultant###Hospital Clínic Barcelona###
Speaker: Jordi Rimola, MD PhD (he/him/his) – Hospital Clínic Barcelona
### he/him/his

15:55 – 16:03 CEST

SO-14: Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover

Favorite

Arndt Vogel, MD – Medizinische Hochschule Hannover ### 716621###Abstract Presenter###Senior Consultant###Medizinische Hochschule Hannover###
Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
###

16:03 – 16:11 CEST

SO-15: Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Abstract Presenter: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra

Favorite

Bruno Sangro, MD, PhD – Clinica Universidad de Navarra ### 1007355###Abstract Presenter###Head, HPB Oncology Area###Clinica Universidad de Navarra###
Abstract Presenter: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra
###

16:11 – 16:19 CEST

SO-16: Proton beam radiotherapy as a valid curative local alternative modality in newly diagnosed hepatocellular carcinoma: comparative study with radiofrequency ablation

Abstract Presenter: Sang Hoon Seo

Favorite

Sang Hoon Seo ### 1977779###Abstract Presenter#########
Abstract Presenter: Sang Hoon Seo
###

16:19 – 16:29 CEST

Discussant: SO-14, SO-15, SO-16

Discussant: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital

Favorite

Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital ### 1252920###Discussant###Consultant Medical Oncologist###Fundacion Jimenez Diaz University Hospital###
Discussant: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital
###

16:29 – 16:50 CEST

Are We Ready to Integrate Systemic Treatment in Early Stages of HCC

Speaker: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center

Favorite

Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Speaker###Professor###Memorial Sloan Kettering Cancer Center###
Speaker: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
###

16:50 – 17:10 CEST

How to Integrate and Sequence New Agents in Advanced HCC?

Speaker: Lorenza Rimassa, MD – Humanitas University and IRCCS Humanitas Research Hospital

Favorite

Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital ### 1666115###Speaker###Associate Professor of Medical Oncology###Humanitas University and IRCCS Humanitas Research Hospital###
Speaker: Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital
### she/her/hers

17:40 – 18:15 CEST

Cases With Panel Discussion: Management Strategy in HCC: Locoregional Treatment vs Systemic Treatment

Moderator: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital

Moderator: Lorenza Rimassa, MD – Humanitas University and IRCCS Humanitas Research Hospital

Panelist: Arndt Vogel, MD – Medizinische Hochschule Hannover

Panelist: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center

Panelist: Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium)

Panelist: Jordi Rimola, MD PhD – Hospital Clínic Barcelona

Favorite

Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital ### 1252920###Moderator###Consultant Medical Oncologist###Fundacion Jimenez Diaz University Hospital###
Moderator: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital
### @@@ Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital ### 1666115###Moderator###Associate Professor of Medical Oncology###Humanitas University and IRCCS Humanitas Research Hospital###
Moderator: Lorenza Rimassa, MD (she/her/hers) – Humanitas University and IRCCS Humanitas Research Hospital
### she/her/hers @@@ Arndt Vogel, MD – Medizinische Hochschule Hannover ### 716621###Panelist###Senior Consultant###Medizinische Hochschule Hannover###
Panelist: Arndt Vogel, MD – Medizinische Hochschule Hannover
### @@@ Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Panelist###Professor###Memorial Sloan Kettering Cancer Center###
Panelist: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
### @@@ Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium) ### 716620###Panelist###Professor###University Hospital Gasthuisberg Leuven (Belgium)###
Panelist: Chris J. Verslype, MD PhD – University Hospital Gasthuisberg Leuven (Belgium)
### @@@ Jordi Rimola, MD PhD (he/him/his) – Hospital Clínic Barcelona ### 1968790###Panelist###Consultant###Hospital Clínic Barcelona###
Panelist: Jordi Rimola, MD PhD (he/him/his) – Hospital Clínic Barcelona
### he/him/his

17:10 – 17:40 CEST
Break and Poster Viewing

17:10 – 17:40 CEST

Break and Poster Viewing

Favorite

17:15 – 17:35 CEST

Poster Discussion Guided Tours - Group 4: Pancreatic Cancer

Poster Discussant: Teresa Macarulla, MD, PhD – Vall d’Hebrón University Hospital

Favorite

Teresa Macarulla, MD, PhD (she/her/hers) – Vall d’Hebrón University Hospital ### 803555###Poster Discussant###Head of Gastrointestinal and Endocrine Tumor Unit###Vall d’Hebrón University Hospital###
Poster Discussant: Teresa Macarulla, MD, PhD (she/her/hers) – Vall d’Hebrón University Hospital
### she/her/hers

17:15 – 17:35 CEST

Poster Discussion Guided Tours - Group 5: Hepatocellular Carcinoma

Poster Discussant: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center

Favorite

Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Poster Discussant###Professor###Memorial Sloan Kettering Cancer Center###
Poster Discussant: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
###

17:15 – 17:35 CEST

Poster Discussion Guided Tours - Group 6: Biliary Tract Cancer and Hepatocellular Carcinoma

Poster Discussant: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital

Favorite

Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital ### 1252920###Poster Discussant###Consultant Medical Oncologist###Fundacion Jimenez Diaz University Hospital###
Poster Discussant: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital
###

17:10 – 17:55 CEST
ESMO Lounge Session: Is Palliative/Supportive Care Different in GI Cancers?
Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute
Session Chair: Rille Pihlak, MD, PhD – St Bart's Hospital

17:10 – 17:55 CEST

ESMO Lounge Session: Is Palliative/Supportive Care Different in GI Cancers?

Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute

Session Chair: Rille Pihlak, MD, PhD – St Bart's Hospital

Favorite

17:10 – 17:20 CEST

Challenges with Diet, Weight Loss, and Bowel/ Biliary Obstruction

Speaker: Jayne Wood, Dr – The Royal Marsden NHS Foundation Trust

Favorite

Jayne Wood, Dr (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1970653###Speaker###Consultant Palliative Medicine###The Royal Marsden NHS Foundation Trust###
Speaker: Jayne Wood, Dr (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers

17:20 – 17:30 CEST

Complex Pain (Coeliac Plexus, Rectal etc.) and Neuropathy

Speaker: Florian Scotte – Gustave Roussy

Favorite

Florian Scotte – Gustave Roussy ### 1940218###Speaker###Head of division###Gustave Roussy###
Speaker: Florian Scotte – Gustave Roussy
###

17:30 – 17:55 CEST

Panel Discussion

Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute

Session Chair: Rille Pihlak, MD, PhD – St Bart's Hospital

Panelist: Florian Scotte – Gustave Roussy

Panelist: Jayne Wood, Dr – The Royal Marsden NHS Foundation Trust

Favorite

Deniz Can Güven, MD – Hacettepe University Cancer Institute ### 1940200###Session Chair###Medical Oncologist###Hacettepe University Cancer Institute###
Session Chair: Deniz Can Güven, MD – Hacettepe University Cancer Institute
### @@@ Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital ### 1293161###Session Chair###Consultant Medical Oncologist###St Bart's Hospital###
Session Chair: Rille Pihlak, MD, PhD (she/her/hers) – St Bart's Hospital
### she/her/hers @@@ Florian Scotte – Gustave Roussy ### 1940218###Panelist###Head of division###Gustave Roussy###
Panelist: Florian Scotte – Gustave Roussy
### @@@ Jayne Wood, Dr (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1970653###Panelist###Consultant Palliative Medicine###The Royal Marsden NHS Foundation Trust###
Panelist: Jayne Wood, Dr (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers

18:15 – 19:15 CEST
Session X: World GI 25th Anniversary Special Session
Chair: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven
Chair: Josep Tabernero, MD – Vall d’Hebron University Hospital
Chair: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay

18:15 – 19:15 CEST

Session X: World GI 25th Anniversary Special Session

Chair: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven

Chair: Josep Tabernero, MD – Vall d’Hebron University Hospital

Chair: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay

Favorite

Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven ### 697455###Chair###Professor of Medicine###University Hospital Gasthuisberg/Leuven###
Chair: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven
### @@@ Josep Tabernero, MD (he/him/his) – Vall d’Hebron University Hospital ### 710542###Chair###Head, Medical Oncology Department###Vall d’Hebron University Hospital###
Chair: Josep Tabernero, MD (he/him/his) – Vall d’Hebron University Hospital
### he/him/his @@@ Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay ### 710546###Chair###Head of Gastrointestinal Oncology Unit###Gustave Roussy, Université Paris-Saclay###
Chair: Michel P. Ducreux, MD, PhD – Gustave Roussy, Université Paris-Saclay
###

18:15 – 18:45 CEST

Immunophenotyping in CRC and/or GI Cancers

Speaker: Jerome Galon, PhD – INSERM

Favorite

Jerome Galon, PhD – INSERM ### 1560502###Speaker###Director###INSERM###
Speaker: Jerome Galon, PhD – INSERM
###

18:45 – 19:15 CEST

WHO and Cancer

Favorite

19:30 – 20:30 CEST
25th Anniversary Celebration Reception; Travel Grant and Young Investigator Award Ceremony

19:30 – 20:30 CEST

25th Anniversary Celebration Reception; Travel Grant and Young Investigator Award Ceremony

Favorite